⌘K
Loading ticker…
As of 2026-08-24, Repligen Corp (RGEN) has a 3-month relative strength percentile of 95 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 63. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.7%, relative volume 1.33×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
RGEN is held by 44 ETFs as of May 2026. Top owner: VHT at 0.10% weight, $20M notional. Top 3 carry $52M.
Held by 127 ETFs · $1.2B across latest filings · largest weight 2.73% (FRTY).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.10% | $20M | — |
| SCHMSchwab U.S. Mid-Cap ETF | 0.12% | $18M | −0.01 pp |
| SCHGSchwab U.S. Large-Cap Growth ETF | 0.02% | $14M | — |
| IVOO | 0.19% | $10M | −0.01 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.01% | $7M | — |
| FNDA | 0.05% | $4M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $4M | — |
| VONVVanguard Russell 1000 Value ETF | 0.02% | $4M | — |
| IVOG | 0.20% | $4M | −0.01 pp |
| ESML | 0.12% | $3M | −0.01 pp |
Showing 10 of 44 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RGEN Jan avg: 5.35% median: 7.39% win: 75% σ: 10.34% n: 4 2022-04-12 → 2026-07-31 | RGEN Feb avg: -5.37% median: -5.04% win: 25% σ: 6.68% n: 4 2022-04-12 → 2026-07-31 | RGEN Mar avg: -9.30% median: -6.83% win: 0% σ: 7.50% n: 4 2022-04-12 → 2026-07-31 | RGEN Apr avg: -3.08% median: -3.62% win: 40% σ: 7.92% n: 5 2022-04-12 → 2026-07-31 | RGEN May avg: -0.71% median: 4.60% win: 60% σ: 10.61% n: 5 2022-04-12 → 2026-07-31 | RGEN Jun avg: -3.41% median: -1.26% win: 40% σ: 11.84% n: 5 2022-04-12 → 2026-07-31 | RGEN Jul avg: 16.58% median: 21.28% win: 80% σ: 17.19% n: 5 2022-04-12 → 2026-07-31 | RGEN Aug avg: -0.29% median: 2.09% win: 75% σ: 6.48% n: 4 2022-04-12 → 2026-07-31 (current) | RGEN Sep avg: -3.85% median: -4.98% win: 25% σ: 10.30% n: 4 2022-04-12 → 2026-07-31 | RGEN Oct avg: -4.03% median: -6.12% win: 25% σ: 11.63% n: 4 2022-04-12 → 2026-07-31 | RGEN Nov avg: 10.43% median: 13.43% win: 75% σ: 8.51% n: 4 2022-04-12 → 2026-07-31 | RGEN Dec avg: 0.11% median: -4.29% win: 25% σ: 9.50% n: 4 2022-04-12 → 2026-07-31 |